Sling ropes in $123m for oral thyroid eye disease drug
Sling Therapeutics has raised $123m to propel its thyroid eye disease (TED) pill through a pivotal clinical trial. The funds,…
16 Sep 2026
Gilead and PAHO agree to expedite lenacapavir access for HIV prevention
Gilead Sciences and the Pan American Health Organization (PAHO) have signed an agreement to expedite access to the company’s twice-yearly lenacapavir injection for human immunodeficiency virus (HIV) prevention as pre-exposure…
16 Sep 2026
Eli Lilly and QurCan sign genetic medicine deal
Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics for diseases of the central and peripheral nervous systems. The…
15 Sep 2026
Electra targets $342m IPO to fund hyperinflammatory syndrome drug’s pivotal trials
Electra Therapeutics has unveiled that it plans to raise up to $341.9m in an initial public offering (IPO), with the funds expected to power Phase III development for its hyperinflammatory…
15 Sep 2026
Agentic AI trust gap slowing healthcare provider adoption, survey reveals
A new survey from digital healthcare security specialist Imprivata has revealed that, while artificial intelligence (AI) is now becoming commonplace in the healthcare workflow, scaled adoption of agentic models lags…
15 Sep 2026
GSK bolsters oncology pipeline with $750m Chimagen TCE deal
GSK has secured the rights to Chimagen Biosciences’ trispecific T-cell engager (TCE) for multiple myeloma, signalling the big pharma company’s remewed interest in oncology following a step away from the…
15 Sep 2026
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine, DT120, following a third successful Phase III readout. The biopharma…